Angiotensin Converting Enzyme Inhibitors Market by Drug Type, Disease Type, Dosage Form, Distribution Channel, Patient Demographics - Global Forecast 2025-2030- Product Image

Sale

Angiotensin Converting Enzyme Inhibitors Market by Drug Type, Disease Type, Dosage Form, Distribution Channel, Patient Demographics - Global Forecast 2025-2030

Report
197 Pages
October 2024
Region: Global
360iResearch™
ID: 6014944

UP TO €667EUR$697USD£555GBP OFF until Dec 31^st 2024

The Angiotensin Converting Enzyme Inhibitors Market grew from USD 3.70 billion in 2023 to USD 3.92 billion in 2024. It is expected to continue growing at a CAGR of 6.23%, reaching USD 5.65 billion by 2030.

Angiotensin Converting Enzyme (ACE) inhibitors are a class of medication primarily used to treat hypertension and congestive heart failure. They function by inhibiting the enzyme responsible for the production of angiotensin II, a compound that narrows blood vessels, thereby increasing blood pressure. The necessity of ACE inhibitors arises due to the escalating prevalence of cardiovascular diseases fueled by lifestyle factors such as poor diet and lack of exercise. Their applications extend to managing diabetic nephropathy and aiding in post-myocardial infarction recovery. End-users predominantly comprise hospitals, clinics, and home care settings. The market growth is influenced by the aging population, increasing health consciousness, and a surge in chronic disease prevalence. However, it faces constraints from potential side effects such as cough, hyperkalemia, and angioedema, coupled with stringent regulatory frameworks. The competitive landscape features intense generic competition affecting pricing dynamics.

Opportunities for growth lie in the development of combination therapies and the expansion of applications in new therapeutic areas. Personalized medicine and patient-centric care models offer untapped avenues for market players. Investing in R&D to improve drug efficacy and reduce adverse effects can carve a competitive edge. Furthermore, strategic collaborations and mergers can enhance market presence and share. However, limitations include high R&D costs, potential adverse drug reactions, and an increasingly saturated market. The regulatory environment poses challenges through rigorous clinical trial phases and approval processes. Innovation should focus on enhancing drug delivery systems, leveraging artificial intelligence for personalized therapies, and exploring alternative therapeutic indications to drive business expansion. The market is dynamic, with rapid advancements in pharmaceutical technology and shifting healthcare priorities necessitating agile strategies to maintain competitiveness. Companies must prioritize adaptive research methodologies and proactive market analysis to anticipate trends and consumer needs effectively.

Understanding Market Dynamics in the Angiotensin Converting Enzyme Inhibitors Market

The Angiotensin Converting Enzyme Inhibitors Market is rapidly evolving, shaped by dynamic supply and demand trends. These insights provide companies with actionable intelligence to drive investments, develop strategies, and seize emerging opportunities. A comprehensive understanding of market dynamics also helps organizations mitigate political, geographical, technical, social, and economic risks while offering a clearer view of consumer behavior and its effects on manufacturing costs and purchasing decisions.

Market Drivers
- Rising prevalence of cardiovascular diseases and hypertension globally driving demand for effective treatment options
- Growing aging population contributing to increased incidence of chronic conditions requiring angiotensin converting enzyme inhibitors
- Advancements in pharmaceutical research and development enhancing efficacy of angiotensin converting enzyme inhibitors
- Government initiatives and healthcare policies supporting the use of angiotensin converting enzyme inhibitors in treatment protocols
Market Restraints
- Increasing availability and preference for alternative treatments for hypertension may reduce demand for angiotensin converting enzyme inhibitors
- Adverse side effects associated with prolonged use of angiotensin converting enzyme inhibitors may reduce patient adherence
Market Opportunities
- Advanced formulation techniques for improved bioavailability and targeted delivery of ace inhibitors
- Opportunities in personalized medicine with customized ace inhibitor treatments based on genetic profiling
- Growing application of ace inhibitors in managing comorbid conditions such as kidney disease and diabetes
Market Challenges
- Competition from alternative therapies and generic drugs challenges the market dominance of angiotensin converting enzyme inhibitors
- Patient adherence and education issues impact the effectiveness and market uptake of angiotensin converting enzyme inhibitors

Exploring Porter’s Five Forces for the Angiotensin Converting Enzyme Inhibitors Market

Porter’s Five Forces framework further strengthens the insights of the Angiotensin Converting Enzyme Inhibitors Market, delivering a clear and effective methodology for understanding the competitive landscape. This tool enables companies to evaluate their current competitive standing and explore strategic repositioning by assessing businesses’ power dynamics and market positioning. It is also instrumental in determining the profitability of new ventures, helping companies leverage their strengths, address weaknesses, and avoid potential pitfalls.

Applying PESTLE Analysis to the Angiotensin Converting Enzyme Inhibitors Market

External macro-environmental factors deeply influence the performance of the Angiotensin Converting Enzyme Inhibitors Market, and the PESTLE analysis provides a comprehensive framework for understanding these influences. By examining Political, Economic, Social, Technological, Legal, and Environmental elements, this analysis offers organizations critical insights into potential opportunities and risks. It also helps businesses anticipate changes in regulations, consumer behavior, and economic trends, enabling them to make informed, forward-looking decisions.

Analyzing Market Share in the Angiotensin Converting Enzyme Inhibitors Market

The Angiotensin Converting Enzyme Inhibitors Market share analysis evaluates vendor performance. This analysis provides a clear view of each vendor’s standing in the competitive landscape by comparing key metrics such as revenue, customer base, and other critical factors. Additionally, it highlights market concentration, fragmentation, and trends in consolidation, empowering vendors to make strategic decisions that enhance their market position.

Evaluating Vendor Success with the FPNV Positioning Matrix in the Angiotensin Converting Enzyme Inhibitors Market

The Angiotensin Converting Enzyme Inhibitors Market FPNV Positioning Matrix is crucial in evaluating vendors based on business strategy and product satisfaction levels. By segmenting vendors into four quadrants - Forefront (F), Pathfinder (P), Niche (N), and Vital (V) - this matrix helps users make well-informed decisions that best align with their unique needs and objectives in the market.

Strategic Recommendations for Success in the Angiotensin Converting Enzyme Inhibitors Market

The Angiotensin Converting Enzyme Inhibitors Market strategic analysis is essential for organizations aiming to strengthen their position in the global market. A comprehensive review of resources, capabilities, and performance helps businesses identify opportunities for improvement and growth. This approach empowers companies to navigate challenges in the increasingly competitive landscape, ensuring they capitalize on new opportunities and align with long-term success.

Key Company Profiles

The report delves into recent significant developments in the Angiotensin Converting Enzyme Inhibitors Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Allergan plc, Amgen Inc., AstraZeneca PLC, Bayer AG, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Daiichi Sankyo Company, Limited, Eli Lilly and Company, Gilead Sciences, Inc., GlaxoSmithKline plc, Johnson & Johnson, Merck & Co., Inc., Mylan N.V., Novartis AG, Pfizer Inc., Roche Holding AG, Sanofi S.A., Takeda Pharmaceutical Company Limited, and Teva Pharmaceutical Industries Ltd..

Market Segmentation & Coverage

This research report categorizes the Angiotensin Converting Enzyme Inhibitors Market to forecast the revenues and analyze trends in each of the following sub-markets:

Drug Type
- Non-Specific ACE Inhibitors
- Specific ACE Inhibitors
Disease Type
- Heart Diseases
  - Chronic Heart Failure
  - Coronary Artery Disease
- Hypertension
  - Primary Hypertension
  - Secondary Hypertension
- Kidney Diseases
  - Chronic Kidney Diseases
  - Diabetic Nephropathy
Dosage Form
- Capsules
- Injectable
- Tablets
Distribution Channel
- Hospital Pharmacies
- Online Pharmacies
- Retail Pharmacies
Patient Demographics
- Adult
- Geriatric
- Pediatric

Region
- Americas
  - Argentina
  - Brazil
  - Canada
  - Mexico
  - United States
    - California
    - Florida
    - Illinois
    - New York
    - Ohio
    - Pennsylvania
    - Texas
- Asia-Pacific
  - Australia
  - China
  - India
  - Indonesia
  - Japan
  - Malaysia
  - Philippines
  - Singapore
  - South Korea
  - Taiwan
  - Thailand
  - Vietnam
- Europe, Middle East & Africa
  - Denmark
  - Egypt
  - Finland
  - France
  - Germany
  - Israel
  - Italy
  - Netherlands
  - Nigeria
  - Norway
  - Poland
  - Qatar
  - Russia
  - Saudi Arabia
  - South Africa
  - Spain
  - Sweden
  - Switzerland
  - Turkey
  - United Arab Emirates
  - United Kingdom

The report provides a detailed overview of the market, exploring several key areas:

Market Penetration: A thorough examination of the current market landscape, featuring comprehensive data from leading industry players and analyzing their reach and influence across the market.
Market Development: The report identifies significant growth opportunities in emerging markets and assesses expansion potential within established segments, providing a roadmap for future development.
Market Diversification: In-depth coverage of recent product launches, untapped geographic regions, significant industry developments, and strategic investments reshaping the market landscape.
Competitive Assessment & Intelligence: A detailed analysis of the competitive landscape, covering market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, technological advancements, and innovations in manufacturing by key market players.
Product Development & Innovation: Insight into groundbreaking technologies, R&D efforts, and product innovations that will drive the market in future.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

What is the current size of the market, and how is it expected to grow?
Which products, segments, and regions present the most attractive investment opportunities?
What are the prevailing technology trends and regulatory factors influencing the market?
How do top vendors rank regarding market share and competitive positioning?
What revenue sources and strategic opportunities guide vendors' market entry or exit decisions?

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary
4. Market Overview

5. Market Insights

5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising prevalence of cardiovascular diseases and hypertension globally driving demand for effective treatment options
5.1.1.2. Growing aging population contributing to increased incidence of chronic conditions requiring angiotensin converting enzyme inhibitors
5.1.1.3. Advancements in pharmaceutical research and development enhancing efficacy of angiotensin converting enzyme inhibitors
5.1.1.4. Government initiatives and healthcare policies supporting the use of angiotensin converting enzyme inhibitors in treatment protocols
5.1.2. Restraints
5.1.2.1. Increasing availability and preference for alternative treatments for hypertension may reduce demand for angiotensin converting enzyme inhibitors
5.1.2.2. Adverse side effects associated with prolonged use of angiotensin converting enzyme inhibitors may reduce patient adherence
5.1.3. Opportunities
5.1.3.1. Advanced formulation techniques for improved bioavailability and targeted delivery of ace inhibitors
5.1.3.2. Opportunities in personalized medicine with customized ace inhibitor treatments based on genetic profiling
5.1.3.3. Growing application of ace inhibitors in managing comorbid conditions such as kidney disease and diabetes
5.1.4. Challenges
5.1.4.1. Competition from alternative therapies and generic drugs challenges the market dominance of angiotensin converting enzyme inhibitors
5.1.4.2. Patient adherence and education issues impact the effectiveness and market uptake of angiotensin converting enzyme inhibitors
5.2. Market Segmentation Analysis
5.3. Porter’s Five Forces Analysis
5.3.1. Threat of New Entrants
5.3.2. Threat of Substitutes
5.3.3. Bargaining Power of Customers
5.3.4. Bargaining Power of Suppliers
5.3.5. Industry Rivalry
5.4. PESTLE Analysis
5.4.1. Political
5.4.2. Economic
5.4.3. Social
5.4.4. Technological
5.4.5. Legal
5.4.6. Environmental

6. Angiotensin Converting Enzyme Inhibitors Market, by Drug Type

6.1. Introduction
6.2. Non-Specific ACE Inhibitors
6.3. Specific ACE Inhibitors

7. Angiotensin Converting Enzyme Inhibitors Market, by Disease Type

7.1. Introduction
7.2. Heart Diseases
7.2.1. Chronic Heart Failure
7.2.2. Coronary Artery Disease
7.3. Hypertension
7.3.1. Primary Hypertension
7.3.2. Secondary Hypertension
7.4. Kidney Diseases
7.4.1. Chronic Kidney Diseases
7.4.2. Diabetic Nephropathy

8. Angiotensin Converting Enzyme Inhibitors Market, by Dosage Form

8.1. Introduction
8.2. Capsules
8.3. Injectable
8.4. Tablets

9. Angiotensin Converting Enzyme Inhibitors Market, by Distribution Channel

9.1. Introduction
9.2. Hospital Pharmacies
9.3. Online Pharmacies
9.4. Retail Pharmacies

10. Angiotensin Converting Enzyme Inhibitors Market, by Patient Demographics

10.1. Introduction
10.2. Adult
10.3. Geriatric
10.4. Pediatric

11. Americas Angiotensin Converting Enzyme Inhibitors Market

11.1. Introduction
11.2. Argentina
11.3. Brazil
11.4. Canada
11.5. Mexico
11.6. United States

12. Asia-Pacific Angiotensin Converting Enzyme Inhibitors Market

12.1. Introduction
12.2. Australia
12.3. China
12.4. India
12.5. Indonesia
12.6. Japan
12.7. Malaysia
12.8. Philippines
12.9. Singapore
12.10. South Korea
12.11. Taiwan
12.12. Thailand
12.13. Vietnam

13. Europe, Middle East & Africa Angiotensin Converting Enzyme Inhibitors Market

13.1. Introduction
13.2. Denmark
13.3. Egypt
13.4. Finland
13.5. France
13.6. Germany
13.7. Israel
13.8. Italy
13.9. Netherlands
13.10. Nigeria
13.11. Norway
13.12. Poland
13.13. Qatar
13.14. Russia
13.15. Saudi Arabia
13.16. South Africa
13.17. Spain
13.18. Sweden
13.19. Switzerland
13.20. Turkey
13.21. United Arab Emirates
13.22. United Kingdom

14. Competitive Landscape

14.1. Market Share Analysis, 2023
14.2. FPNV Positioning Matrix, 2023
14.3. Competitive Scenario Analysis
14.4. Strategy Analysis & Recommendation

List of Figures

FIGURE 1. ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET RESEARCH PROCESS
FIGURE 2. ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
FIGURE 7. GLOBAL ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 8. GLOBAL ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISEASE TYPE, 2023 VS 2030 (%)
FIGURE 9. GLOBAL ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISEASE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 10. GLOBAL ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DOSAGE FORM, 2023 VS 2030 (%)
FIGURE 11. GLOBAL ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DOSAGE FORM, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 12. GLOBAL ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
FIGURE 13. GLOBAL ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 14. GLOBAL ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2023 VS 2030 (%)
FIGURE 15. GLOBAL ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 16. AMERICAS ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 17. AMERICAS ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 18. UNITED STATES ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 19. UNITED STATES ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 20. ASIA-PACIFIC ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 21. ASIA-PACIFIC ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 24. ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 25. ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET, FPNV POSITIONING MATRIX, 2023

List of Tables

TABLE 1. ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET DYNAMICS
TABLE 7. GLOBAL ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY NON-SPECIFIC ACE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY SPECIFIC ACE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY HEART DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY CHRONIC HEART FAILURE, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY CORONARY ARTERY DISEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY HEART DISEASES, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY HYPERTENSION, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY PRIMARY HYPERTENSION, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY SECONDARY HYPERTENSION, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY HYPERTENSION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY KIDNEY DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY CHRONIC KIDNEY DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DIABETIC NEPHROPATHY, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY KIDNEY DISEASES, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY CAPSULES, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY TABLETS, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY ADULT, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. AMERICAS ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 36. AMERICAS ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 37. AMERICAS ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY HEART DISEASES, 2018-2030 (USD MILLION)
TABLE 38. AMERICAS ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY HYPERTENSION, 2018-2030 (USD MILLION)
TABLE 39. AMERICAS ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY KIDNEY DISEASES, 2018-2030 (USD MILLION)
TABLE 40. AMERICAS ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 41. AMERICAS ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 42. AMERICAS ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 43. AMERICAS ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 44. ARGENTINA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 45. ARGENTINA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 46. ARGENTINA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY HEART DISEASES, 2018-2030 (USD MILLION)
TABLE 47. ARGENTINA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY HYPERTENSION, 2018-2030 (USD MILLION)
TABLE 48. ARGENTINA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY KIDNEY DISEASES, 2018-2030 (USD MILLION)
TABLE 49. ARGENTINA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 50. ARGENTINA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 51. ARGENTINA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 52. BRAZIL ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 53. BRAZIL ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 54. BRAZIL ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY HEART DISEASES, 2018-2030 (USD MILLION)
TABLE 55. BRAZIL ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY HYPERTENSION, 2018-2030 (USD MILLION)
TABLE 56. BRAZIL ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY KIDNEY DISEASES, 2018-2030 (USD MILLION)
TABLE 57. BRAZIL ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 58. BRAZIL ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 59. BRAZIL ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 60. CANADA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 61. CANADA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 62. CANADA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY HEART DISEASES, 2018-2030 (USD MILLION)
TABLE 63. CANADA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY HYPERTENSION, 2018-2030 (USD MILLION)
TABLE 64. CANADA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY KIDNEY DISEASES, 2018-2030 (USD MILLION)
TABLE 65. CANADA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 66. CANADA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 67. CANADA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 68. MEXICO ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 69. MEXICO ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 70. MEXICO ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY HEART DISEASES, 2018-2030 (USD MILLION)
TABLE 71. MEXICO ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY HYPERTENSION, 2018-2030 (USD MILLION)
TABLE 72. MEXICO ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY KIDNEY DISEASES, 2018-2030 (USD MILLION)
TABLE 73. MEXICO ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 74. MEXICO ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 75. MEXICO ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 76. UNITED STATES ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 77. UNITED STATES ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 78. UNITED STATES ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY HEART DISEASES, 2018-2030 (USD MILLION)
TABLE 79. UNITED STATES ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY HYPERTENSION, 2018-2030 (USD MILLION)
TABLE 80. UNITED STATES ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY KIDNEY DISEASES, 2018-2030 (USD MILLION)
TABLE 81. UNITED STATES ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 82. UNITED STATES ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 83. UNITED STATES ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 84. UNITED STATES ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 85. ASIA-PACIFIC ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 86. ASIA-PACIFIC ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 87. ASIA-PACIFIC ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY HEART DISEASES, 2018-2030 (USD MILLION)
TABLE 88. ASIA-PACIFIC ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY HYPERTENSION, 2018-2030 (USD MILLION)
TABLE 89. ASIA-PACIFIC ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY KIDNEY DISEASES, 2018-2030 (USD MILLION)
TABLE 90. ASIA-PACIFIC ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 91. ASIA-PACIFIC ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 92. ASIA-PACIFIC ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 93. ASIA-PACIFIC ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 94. AUSTRALIA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 95. AUSTRALIA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 96. AUSTRALIA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY HEART DISEASES, 2018-2030 (USD MILLION)
TABLE 97. AUSTRALIA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY HYPERTENSION, 2018-2030 (USD MILLION)
TABLE 98. AUSTRALIA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY KIDNEY DISEASES, 2018-2030 (USD MILLION)
TABLE 99. AUSTRALIA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 100. AUSTRALIA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 101. AUSTRALIA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 102. CHINA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 103. CHINA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 104. CHINA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY HEART DISEASES, 2018-2030 (USD MILLION)
TABLE 105. CHINA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY HYPERTENSION, 2018-2030 (USD MILLION)
TABLE 106. CHINA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY KIDNEY DISEASES, 2018-2030 (USD MILLION)
TABLE 107. CHINA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 108. CHINA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 109. CHINA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 110. INDIA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 111. INDIA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 112. INDIA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY HEART DISEASES, 2018-2030 (USD MILLION)
TABLE 113. INDIA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY HYPERTENSION, 2018-2030 (USD MILLION)
TABLE 114. INDIA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY KIDNEY DISEASES, 2018-2030 (USD MILLION)
TABLE 115. INDIA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 116. INDIA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 117. INDIA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 118. INDONESIA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 119. INDONESIA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 120. INDONESIA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY HEART DISEASES, 2018-2030 (USD MILLION)
TABLE 121. INDONESIA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY HYPERTENSION, 2018-2030 (USD MILLION)
TABLE 122. INDONESIA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY KIDNEY DISEASES, 2018-2030 (USD MILLION)
TABLE 123. INDONESIA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 124. INDONESIA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 125. INDONESIA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 126. JAPAN ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 127. JAPAN ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 128. JAPAN ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY HEART DISEASES, 2018-2030 (USD MILLION)
TABLE 129. JAPAN ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY HYPERTENSION, 2018-2030 (USD MILLION)
TABLE 130. JAPAN ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY KIDNEY DISEASES, 2018-2030 (USD MILLION)
TABLE 131. JAPAN ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 132. JAPAN ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 133. JAPAN ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 134. MALAYSIA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 135. MALAYSIA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 136. MALAYSIA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY HEART DISEASES, 2018-2030 (USD MILLION)
TABLE 137. MALAYSIA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY HYPERTENSION, 2018-2030 (USD MILLION)
TABLE 138. MALAYSIA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY KIDNEY DISEASES, 2018-2030 (USD MILLION)
TABLE 139. MALAYSIA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 140. MALAYSIA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 141. MALAYSIA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 142. PHILIPPINES ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 143. PHILIPPINES ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 144. PHILIPPINES ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY HEART DISEASES, 2018-2030 (USD MILLION)
TABLE 145. PHILIPPINES ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY HYPERTENSION, 2018-2030 (USD MILLION)
TABLE 146. PHILIPPINES ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY KIDNEY DISEASES, 2018-2030 (USD MILLION)
TABLE 147. PHILIPPINES ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 148. PHILIPPINES ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 149. PHILIPPINES ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 150. SINGAPORE ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 151. SINGAPORE ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 152. SINGAPORE ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY HEART DISEASES, 2018-2030 (USD MILLION)
TABLE 153. SINGAPORE ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY HYPERTENSION, 2018-2030 (USD MILLION)
TABLE 154. SINGAPORE ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY KIDNEY DISEASES, 2018-2030 (USD MILLION)
TABLE 155. SINGAPORE ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 156. SINGAPORE ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 157. SINGAPORE ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 158. SOUTH KOREA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 159. SOUTH KOREA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 160. SOUTH KOREA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY HEART DISEASES, 2018-2030 (USD MILLION)
TABLE 161. SOUTH KOREA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY HYPERTENSION, 2018-2030 (USD MILLION)
TABLE 162. SOUTH KOREA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY KIDNEY DISEASES, 2018-2030 (USD MILLION)
TABLE 163. SOUTH KOREA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 164. SOUTH KOREA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 165. SOUTH KOREA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 166. TAIWAN ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 167. TAIWAN ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 168. TAIWAN ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY HEART DISEASES, 2018-2030 (USD MILLION)
TABLE 169. TAIWAN ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY HYPERTENSION, 2018-2030 (USD MILLION)
TABLE 170. TAIWAN ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY KIDNEY DISEASES, 2018-2030 (USD MILLION)
TABLE 171. TAIWAN ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 172. TAIWAN ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 173. TAIWAN ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 174. THAILAND ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 175. THAILAND ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 176. THAILAND ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY HEART DISEASES, 2018-2030 (USD MILLION)
TABLE 177. THAILAND ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY HYPERTENSION, 2018-2030 (USD MILLION)
TABLE 178. THAILAND ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY KIDNEY DISEASES, 2018-2030 (USD MILLION)
TABLE 179. THAILAND ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 180. THAILAND ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 181. THAILAND ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 182. VIETNAM ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 183. VIETNAM ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 184. VIETNAM ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY HEART DISEASES, 2018-2030 (USD MILLION)
TABLE 185. VIETNAM ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY HYPERTENSION, 2018-2030 (USD MILLION)
TABLE 186. VIETNAM ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY KIDNEY DISEASES, 2018-2030 (USD MILLION)
TABLE 187. VIETNAM ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 188. VIETNAM ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 189. VIETNAM ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 190. EUROPE, MIDDLE EAST & AFRICA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 191. EUROPE, MIDDLE EAST & AFRICA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 192. EUROPE, MIDDLE EAST & AFRICA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY HEART DISEASES, 2018-2030 (USD MILLION)
TABLE 193. EUROPE, MIDDLE EAST & AFRICA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY HYPERTENSION, 2018-2030 (USD MILLION)
TABLE 194. EUROPE, MIDDLE EAST & AFRICA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY KIDNEY DISEASES, 2018-2030 (USD MILLION)
TABLE 195. EUROPE, MIDDLE EAST & AFRICA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 196. EUROPE, MIDDLE EAST & AFRICA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 197. EUROPE, MIDDLE EAST & AFRICA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 198. EUROPE, MIDDLE EAST & AFRICA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 199. DENMARK ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 200. DENMARK ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 201. DENMARK ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY HEART DISEASES, 2018-2030 (USD MILLION)
TABLE 202. DENMARK ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY HYPERTENSION, 2018-2030 (USD MILLION)
TABLE 203. DENMARK ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY KIDNEY DISEASES, 2018-2030 (USD MILLION)
TABLE 204. DENMARK ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 205. DENMARK ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 206. DENMARK ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 207. EGYPT ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 208. EGYPT ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 209. EGYPT ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY HEART DISEASES, 2018-2030 (USD MILLION)
TABLE 210. EGYPT ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY HYPERTENSION, 2018-2030 (USD MILLION)
TABLE 211. EGYPT ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY KIDNEY DISEASES, 2018-2030 (USD MILLION)
TABLE 212. EGYPT ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 213. EGYPT ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 214. EGYPT ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 215. FINLAND ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 216. FINLAND ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 217. FINLAND ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY HEART DISEASES, 2018-2030 (USD MILLION)
TABLE 218. FINLAND ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY HYPERTENSION, 2018-2030 (USD MILLION)
TABLE 219. FINLAND ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY KIDNEY DISEASES, 2018-2030 (USD MILLION)
TABLE 220. FINLAND ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 221. FINLAND ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 222. FINLAND ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 223. FRANCE ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 224. FRANCE ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 225. FRANCE ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY HEART DISEASES, 2018-2030 (USD MILLION)
TABLE 226. FRANCE ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY HYPERTENSION, 2018-2030 (USD MILLION)
TABLE 227. FRANCE ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY KIDNEY DISEASES, 2018-2030 (USD MILLION)
TABLE 228. FRANCE ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 229. FRANCE ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 230. FRANCE ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 231. GERMANY ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 232. GERMANY ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 233. GERMANY ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY HEART DISEASES, 2018-2030 (USD MILLION)
TABLE 234. GERMANY ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY HYPERTENSION, 2018-2030 (USD MILLION)
TABLE 235. GERMANY ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY KIDNEY DISEASES, 2018-2030 (USD MILLION)
TABLE 236. GERMANY ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 237. GERMANY ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 238. GERMANY ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 239. ISRAEL ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 240. ISRAEL ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 241. ISRAEL ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY HEART DISEASES, 2018-2030 (USD MILLION)
TABLE 242. ISRAEL ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY HYPERTENSION, 2018-2030 (USD MILLION)
TABLE 243. ISRAEL ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY KIDNEY DISEASES, 2018-2030 (USD MILLION)
TABLE 244. ISRAEL ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 245. ISRAEL ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 246. ISRAEL ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 247. ITALY ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 248. ITALY ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 249. ITALY ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY HEART DISEASES, 2018-2030 (USD MILLION)
TABLE 250. ITALY ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY HYPERTENSION, 2018-2030 (USD MILLION)
TABLE 251. ITALY ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY KIDNEY DISEASES, 2018-2030 (USD MILLION)
TABLE 252. ITALY ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 253. ITALY ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 254. ITALY ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 255. NETHERLANDS ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 256. NETHERLANDS ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 257. NETHERLANDS ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY HEART DISEASES, 2018-2030 (USD MILLION)
TABLE 258. NETHERLANDS ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY HYPERTENSION, 2018-2030 (USD MILLION)
TABLE 259. NETHERLANDS ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY KIDNEY DISEASES, 2018-2030 (USD MILLION)
TABLE 260. NETHERLANDS ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 261. NETHERLANDS ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 262. NETHERLANDS ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 263. NIGERIA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 264. NIGERIA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 265. NIGERIA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY HEART DISEASES, 2018-2030 (USD MILLION)
TABLE 266. NIGERIA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY HYPERTENSION, 2018-2030 (USD MILLION)
TABLE 267. NIGERIA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY KIDNEY DISEASES, 2018-2030 (USD MILLION)
TABLE 268. NIGERIA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 269. NIGERIA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 270. NIGERIA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 271. NORWAY ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 272. NORWAY ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 273. NORWAY ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY HEART DISEASES, 2018-2030 (USD MILLION)
TABLE 274. NORWAY ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY HYPERTENSION, 2018-2030 (USD MILLION)
TABLE 275. NORWAY ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY KIDNEY DISEASES, 2018-2030 (USD MILLION)
TABLE 276. NORWAY ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 277. NORWAY ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 278. NORWAY ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 279. POLAND ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 280. POLAND ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 28

Companies Mentioned

The leading players in the Angiotensin Converting Enzyme Inhibitors Market, which are profiled in this report, include:

AbbVie Inc.
Allergan plc
Amgen Inc.
AstraZeneca PLC
Bayer AG
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Company
Daiichi Sankyo Company, Limited
Eli Lilly and Company
Gilead Sciences, Inc.
GlaxoSmithKline plc
Johnson & Johnson
Merck & Co., Inc.
Mylan N.V.
Novartis AG
Pfizer Inc.
Roche Holding AG
Sanofi S.A.
Takeda Pharmaceutical Company Limited
Teva Pharmaceutical Industries Ltd.

Methodology

LOADING...

Table Information

Report Attribute	Details
No. of Pages	197
Published	October 2024
Forecast Period	2024 - 2030
Estimated Market Value ( USD ) in 2024	$ 3.92 Billion
Forecasted Market Value ( USD ) by 2030	$ 5.65 Billion
Compound Annual Growth Rate	6.2%
Regions Covered	Global
No. of Companies Mentioned	20

License	Format	Properties	Price
SINGLE USER LICENSE PDF, Excel and Online Access		This is a single user license, allowing one user access to the product.	€3392EUR$3,545USD£2,823GBP €3769EUR$3,939USD£3,136GBP
ENTERPRISE LICENSE PDF, Excel and Online Access		This is an enterprise license, allowing all employees within your organization access to the product.	€6002EUR$6,272USD£4,994GBP €6668EUR$6,969USD£5,549GBP

Understanding Market Dynamics in the Angiotensin Converting Enzyme Inhibitors Market

Exploring Porter’s Five Forces for the Angiotensin Converting Enzyme Inhibitors Market

Applying PESTLE Analysis to the Angiotensin Converting Enzyme Inhibitors Market

Analyzing Market Share in the Angiotensin Converting Enzyme Inhibitors Market

Evaluating Vendor Success with the FPNV Positioning Matrix in the Angiotensin Converting Enzyme Inhibitors Market

Strategic Recommendations for Success in the Angiotensin Converting Enzyme Inhibitors Market

Key Company Profiles

Market Segmentation & Coverage

The report provides a detailed overview of the market, exploring several key areas:

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

Table of Contents

Companies Mentioned

Methodology

Table Information

Related Topics

Related Reports

Angiotensin Converting Enzyme (ACE) Inhibitors Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2022 to 2030

Angiotensin Converting Enzyme (ACE) Inhibitors - Global Strategic Business Report

Dilated Cardiomyopathy Therapeutics - Global Strategic Business Report

Angiotensin-converting Enzyme (ACE) Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast - 2034

Angiotensin Converting Enzyme Inhibitors Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application, Product Type